Accolade, Inc. ACCD
Set alert
7.02 0.00 0.00%
At close · Apr 8
7.02 Day range 7.02
52-week range unavailable
- YTD
- +105.26%
- 1 year
- -23.61%
- Open
- 7.02
- Prev close
- 7.02
- Mkt cap
- 273.83M
- Vol
- 4.54M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.02
- High
- 7.02
- Forward P/E
- -4.05
- Beta
- 2.02
- Short ratio
- 2.59
- Inst. own
- 83.49%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Jan 9, 2025
- 50-d avg
- 3.51
- 200-d avg
- 5.37
- 1y target
- 7.17
2Y chart
Events in this range
- Apr 25, 2024Earnings: -0.1; estimate -0.11; surprise 9.09%
- Apr 25, 2024Earnings: —; estimate -0.11; surprise —%
- Jun 27, 2024Earnings: -0.35; estimate -0.48; surprise 27.08%
- Jun 27, 2024Earnings: —; estimate -0.48; surprise —%
- Oct 8, 2024Earnings: -0.3; estimate -0.45; surprise 33.33%
- Oct 9, 2024Rating: Stephens & Co. · Overweight → Overweight
- Oct 9, 2024Rating: Barclays · Equal-Weight → Equal-Weight
- Oct 9, 2024Rating: Canaccord Genuity · Buy → Buy
- Oct 9, 2024Rating: Truist Securities · Buy → Buy
- Oct 11, 2024Rating: Wells Fargo · Equal-Weight → Equal-Weight
- Dec 17, 2024Rating: Morgan Stanley · Equal-Weight → Equal-Weight
Signals (72)
| Name | Date | Ago |
|---|---|---|
| RSI: Overbought | Apr 3, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 30, 2025 | 1 year ago |
| SMA: Bullish | Jan 8, 2025 | 1 year ago |
| SMA: Bullish | Jan 8, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 8, 2025 | 1 year ago |
| RSI: Overbought | Jan 8, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 7, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 6, 2025 | 1 year ago |
| SMA: Bearish | Dec 30, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 30, 2024 | 1 year ago |
| MACD: Buy Signal | Dec 27, 2024 | 1 year ago |
| SMA: Bullish | Dec 26, 2024 | 1 year ago |
| SMA: Bearish | Dec 12, 2024 | 1 year ago |
| SMA: Bullish | Dec 6, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 5, 2024 | 1 year ago |
| SMA: Bearish | Dec 3, 2024 | 1 year ago |
| SMA: Bullish | Nov 21, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 6, 2024 | 1 year ago |
| RSI: Oversold | Oct 23, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 14, 2024 | 2 years ago |
| SMA: Bearish | Oct 9, 2024 | 2 years ago |
| SMA: Bullish | Oct 8, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 8, 2024 | 2 years ago |
| SMA: Bearish | Sep 20, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 20, 2024 | 2 years ago |
| MACD: Buy Signal | Sep 17, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 6, 2024 | 2 years ago |
| SMA: Bullish | Aug 23, 2024 | 2 years ago |
| RSI: Oversold | Jul 18, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 16, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 28, 2024 | 2 years ago |
| RSI: Oversold | Jun 28, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 26, 2024 | 2 years ago |
| RSI: Oversold | Jun 20, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 11, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 6, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 4, 2024 | 2 years ago |
| MACD: Buy Signal | May 15, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 29, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 19, 2024 | 2 years ago |
| MACD: Sell Signal | Apr 11, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 18, 2024 | 2 years ago |
| SMA: Bearish | Feb 22, 2024 | 2 years ago |
| SMA: Bearish | Feb 20, 2024 | 2 years ago |
| MACD: Sell Signal | Feb 16, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 8, 2024 | 2 years ago |
| SMA: Bullish | Feb 1, 2024 | 2 years ago |
| SMA: Bearish | Jan 31, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 17, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 9, 2024 | 2 years ago |
| RSI: Overbought | Jan 9, 2024 | 2 years ago |
| MACD: Sell Signal | Jan 4, 2024 | 2 years ago |
| RSI: Overbought | Dec 21, 2023 | 2 years ago |
| RSI: Overbought | Dec 8, 2023 | 2 years ago |
| SMA: Bullish | Nov 27, 2023 | 2 years ago |
| MACD: Buy Signal | Oct 25, 2023 | 3 years ago |
| RSI: Oversold | Sep 21, 2023 | 3 years ago |
| RSI: Oversold | Sep 19, 2023 | 3 years ago |
| MACD: Sell Signal | Sep 6, 2023 | 3 years ago |
| SMA: Bearish | Sep 5, 2023 | 3 years ago |
| SMA: Bullish | Sep 1, 2023 | 3 years ago |
| MACD: Buy Signal | Sep 1, 2023 | 3 years ago |
| SMA: Bearish | Aug 31, 2023 | 3 years ago |
| SMA: Bullish | Aug 29, 2023 | 3 years ago |
| SMA: Bearish | Aug 16, 2023 | 3 years ago |
| MACD: Sell Signal | Aug 9, 2023 | 3 years ago |
| MACD: Buy Signal | Jul 11, 2023 | 3 years ago |
| SMA: Bullish | Jul 10, 2023 | 3 years ago |
| SMA: Bearish | Jul 5, 2023 | 3 years ago |
| SMA: Bullish | Jun 30, 2023 | 3 years ago |
| MACD: Sell Signal | Jun 23, 2023 | 3 years ago |
| SMA: Bearish | Jun 22, 2023 | 3 years ago |
Key statistics
- Market cap
- 273.83M
- Enterprise value
- 284.73M
- Trailing P/E
- 0.00
- Forward P/E
- -4.05
- PEG ratio
- 0.00
- Price / sales
- 0.62
- Price / book
- 0.65
- EPS (TTM)
- -1.02
- Beta
- 2.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -18.16%
- Revenue (TTM)
- 441.03M
- Revenue growth
- 9.80%
- Free cash flow
- 33.37M
- Total cash
- 234.35M
- Total debt
- 238.81M
- Return on equity
- -18.61%
- Shares outstanding
- 80.54M
- Short % of float
- 4.02%
- 50-day average
- 3.51
- 200-day average
- 5.37
Analyst view
Consensus: buy
Buy
Price target (mean) 7.17 +2.2% upside
Now 7.02
- Target (low)
- 5.00
- Target (mean)
- 7.17
- Target (high)
- 9.50
Ratings (0m) 14 11 buy · 3 hold · 0 sell
- Strong buy3
- Buy8
- Hold3
- Sell0
- Strong sell0
Next earnings
Jan 9, 2025
Expected Jan 9, 2025. Consensus EPS estimate -0.16.
Financials — quick view
ACCD Revenue — quarterly 105.06M
ACCD Net income — quarterly -121.26M
ACCD EPS — quarterly -1.50
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 9, 2025 | Nov 1, 2024 | -0.31 | — | — | — |
| Oct 8, 2024 | Aug 1, 2024 | -0.45 | -0.30 | +0.15 | +33.33% |
| Jun 27, 2024 | May 1, 2024 | -0.48 | -0.35 | +0.13 | +27.08% |
| Jun 27, 2024 | May 1, 2024 | -0.48 | — | — | — |
| Apr 25, 2024 | Feb 1, 2024 | -0.11 | -0.10 | +0.01 | +9.09% |
| Apr 25, 2024 | Feb 1, 2024 | -0.11 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Oct 11, 2024 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 9, 2024 | Truist Securities | main | Buy | Buy |
| Oct 9, 2024 | Canaccord Genuity | main | Buy | Buy |
| Oct 9, 2024 | Barclays | main | Equal-Weight | Equal-Weight |
| Oct 9, 2024 | Stephens & Co. | main | Overweight | Overweight |
About Accolade, Inc.
Accolade, Inc., together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians. It also provides medical opinion services to commercial customers; and navigation, care, and advocacy solutions. In addition, the company offers medical consultations that connect patients to qualified condition-specific specialists for adult and pediatric care; and primary care and mental health support solutions. It serves employers who provide employees and their families a single place to turn for their health, healthcare, and benefits needs. The company was incorporated in 2007 and is headquartered in Seattle, Washington.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- accolade.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on ACCD — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BARNES STEPHEN H. | Chief Financial Officer | Sale | Dec 16, 2024 | 220,463 |
| BRODSKY JEFFREY S | Director | Conversion of Exercise of derivative security | Dec 1, 2024 | 44,632 |
| CAVANAUGH ROBERT N | President | Sale | Dec 16, 2024 | 213,295 |
| ESKEW RICHARD | General Counsel | Sale | Dec 2, 2024 | 62,507 |
| HILTON MICHAEL W. | Director | Conversion of Exercise of derivative security | Dec 15, 2024 | 345,988 |
| KLEIN PETER S | Director | Conversion of Exercise of derivative security | Aug 5, 2024 | 28,329 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.75% | 6,240,828 | 21.22M | Sep 29, 2024 |
| Ah Capital Management, L.L.C. | 6.70% | 5,398,708 | 18.36M | Sep 29, 2024 |
| ARK Investment Management, LLC | 6.68% | 5,382,533 | 18.30M | Sep 29, 2024 |
| Brown Advisory Inc. | 5.99% | 4,824,662 | 16.40M | Sep 29, 2024 |
| Vanguard Group Inc | 5.16% | 4,157,154 | 14.13M | Sep 29, 2024 |
| Millennium Management Llc | 4.95% | 3,987,883 | 13.56M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Tr-ARK Genomic Revolution ETF | 6.49% | 5,223,950 | 17.76M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.75% | 2,213,022 | 7.52M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.28% | 1,837,885 | 6.25M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.41% | 1,139,503 | 3.87M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.94% | 759,285 | 2.58M | Aug 30, 2024 |
| iShares Russell 2000 Value ETF | 0.57% | 463,027 | 1.57M | Oct 30, 2024 |